TY  - GEN
AU  - Sullivan,Ryan J
AU  - Infante,Jeffrey R
AU  - Janku,Filip
AU  - Wong,Deborah Jean Lee
AU  - Sosman,Jeffrey A
AU  - Keedy,Vicki
AU  - Patel,Manish R
AU  - Shapiro,Geoffrey I
AU  - Mier,James W
AU  - Tolcher,Anthony W
AU  - Wang-Gillam,Andrea
AU  - Sznol,Mario
AU  - Flaherty,Keith
AU  - Buchbinder,Elizabeth
AU  - Carvajal,Richard D
AU  - Varghese,Anna M
AU  - Lacouture,Mario E
AU  - Ribas,Antoni
AU  - Patel,Sapna P
AU  - DeCrescenzo,Gary A
AU  - Emery,Caroline M
AU  - Groover,Anna L
AU  - Saha,Saurabh
AU  - Varterasian,Mary
AU  - Welsch,Dean J
AU  - Hyman,David M
AU  - Li,Bob T
TI  - First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
SN  - 2159-8290
PY  - 2019///0604
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Aminopyridines
KW  - pharmacology
KW  - Female
KW  - Humans
KW  - Magnetic Resonance Imaging
KW  - Male
KW  - Middle Aged
KW  - Mitogen-Activated Protein Kinase 1
KW  - antagonists & inhibitors
KW  - Mitogen-Activated Protein Kinase 3
KW  - Mitogen-Activated Protein Kinases
KW  - genetics
KW  - Mutation
KW  - Neoplasm Staging
KW  - Neoplasms
KW  - diagnosis
KW  - Protein Kinase Inhibitors
KW  - Pyrroles
KW  - Tomography, X-Ray Computed
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/2159-8290.CD-17-1119
ER  -